Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
NEW YORK (Reuters Health) – High-dose chemo followed by autologous stem-cell transplantation achieves good results in patients with relapsed Hodgkin’s lymphoma, and outcomes are not improved by additional…
NEW YORK (Reuters Health) – In order to minimize the risk of potential harms, erythropoiesis-stimulating agents (ESAs) in patients undergoing myelosuppressive chemotherapy should be administered at the lowest…
NEW YORK (Reuters Health) – Adding the anti-VEGF monoclonal antibody bevacizumab to state-of-the-art adjuvant chemotherapy for stage II or III colon cancer does not improve disease-free survival, according…
NEW YORK (Reuters Health) – Rofecoxib used as adjuvant therapy does not improve survival or reduce recurrences in patients who have undergone surgery for colorectal cancer, according to…
NEW YORK (Reuters Health) – Adding interferon alpha-2b and megadose vitamins to treatment with intravesical BCG does not improve outcomes in patients with non-muscle invasive bladder cancer. In…
NEW YORK (Reuters Health) – The tyrosine-kinase inhibitor pazopanib seems to be a promising option for treating progressive metastatic differentiated thyroid cancer that is unresponsive to radioiodine therapy,…
NEW YORK (Reuters Health) – Response rates are higher when bortezomib plus dexamethasone rather than vincristine plus doxorubicin plus dexamethasone (VAD) is used as induction therapy before stem-cell…
NEW YORK (Reuters Health) – Men whose baseline PSA is less than 2.0 ng/mL are unlikely to benefit from further screening for prostate cancer, according to findings reported…
NEW YORK (Reuters Health) – A finding of homozygosity for mutations that cause Gaucher disease in patients who report no symptoms of the disorder warrants further followup. Manifestations…
NEW YORK (Reuters Health) – HER2 protein and gene expression predict the response of breast cancer patients to adjuvant trastuzumab therapy, but which test provides the best information?…
